Article
FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†.
European urology - 1 Nov 2020
van Rhijn Bas W G, Mertens Laura S, Mayr Roman, Bostrom Peter J, Real Francisco X, Zwarthoff Ellen C, Boormans Joost L, Abas Cheno, van Leenders Geert J L H, Götz Stefanie, Hippe Katrin, Bertz Simone, Neuzillet Yann, Sanders Joyce, Broeks Annegien, van der Heijden Michiel S, Jewett Michael A S, Marquez Mirari, Stoehr Robert, Zlotta Alexandre R, Eckstein Markus, Soorojebally Yanish, Roshani Hossain, Burger Maximilian, Otto Wolfgang, Radvanyi François, Sirab Nanor, Pouessel Damien, Wullich Bernd, van der Kwast Theo H, Malats Núria, Hartmann Arndt, Allory Yves, Zuiverloon Tahlita C M
Abstract excerpt
Fibroblast growth factor receptor 3 (FGFR3) is an actionable target in bladder cancer (BC). FGFR3 mutations are common in noninvasive BC and associated with favorable BC prognosis. Overexpression was reported in up to 40% of FGFR3 wild-type muscle-invasive BC. We analyzed FGFR3 mutations, FGFR3, and p53 protein expression and assessed their prognostic value in a cohort of 1000 chemotherapy-naive radical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.